Cefiderocol for the treatment of infections due to aerobic gram-negative bacteria in adult patients with limited treatment options
Norwegian Medicines Agency (NOMA)
Record ID 32018001147
Authors' objectives: This is the pharmaceutical Joint Assessment PTJA11 – Cefiderocol for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options. In April 2020, the European Commission granted marketing authorisation for Fetcroja® (cefiderocol) for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options. This Joint Assessment aims to compare the clinical effectiveness and safety of cefiderocol in the target patient populations with relevant comparators according to the national requirements of EUnetHTA partners.
Project Status: Completed
URL for protocol: https://eunethta.eu/ptja11/
Year Published: 2020
URL for published report: https://eunethta.eu/ptja11/
Requestor: HTA agencies
English language abstract: An English language summary is available
Publication Type: Rapid Review
- Anti-Bacterial Agents
- Gram-Negative Bacteria
- Gram-Negative Bacterial Infections
Organisation Name: European Network for Health Technology Assessment
Contact Email: firstname.lastname@example.org
Copyright: CC-BY-NC: You may copy, distribute, display, perform, and modify and use the EUnetHTA work for any purpose other than commercially unless you get your permission first.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.